A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma. Issue 7 (7th June 2022) - Bond, David A.; Huang, Ying; Christian, Beth A.; Jaglowski, Samantha; Benson, Don; Alinari, Lapo; Baiocchi, Robert A.; Cohen, Jonathon B.; Blum, Kristie A.; Maddocks, Kami J.